Skip to main content
Top
Published in: Respiratory Research 1/2020

Open Access 01-12-2020 | Tuberculosis | Research

The impact on incident tuberculosis by kidney function impairment status: analysis of severity relationship

Authors: Chin-Chung Shu, Yu-Feng Wei, Yi-Chun Yeh, Hsien-Ho Lin, Chung-Yu Chen, Ping-Huai Wang, Shih-Lung Cheng, Jann-Yuan Wang, Chong-Jen Yu

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Background

The risk of tuberculosis (TB) in patients with impaired kidney function remains unclear by different stages of renal function impairment.

Methods

We retrospectively recruited all patients with kidney function in a tertiary-care referral center from January 2008 to December 2013 and followed them till December 2016. We defined the primary outcome as active TB development and analyzed the impact of kidney function impairment.

Results

During the study period, a total of 289,579 patients were enrolled for analysis, and of them, 1012 patients had active TB events in an average of 4.13 years of follow-up. According to kidney function impairment, the incidence rate of TB was similar in patients with no chronic kidney disease (CKD) or stage 1 and stage 2, and it increased apparently at stage 3a (167.68 per 100,000 person-years) to stage 3b, stage 4 and stage 5 (229.25, 304.95 and 349.29 per 100,000 person-years, respectively). In a Cox proportional hazard regression model, the dose response of TB risk among different stages of kidney function impairment increased significantly from CKD stage 3a to stage 5. Patients with long-term dialysis had a hazard ratio of 2.041 (1.092–3.815, p = 0.0254), which is similar to that of stage 4 CKD but lower than that of stage 5.

Conclusion

In patients with impaired kidney function, the risk of TB increases from CKD stage 3, and in stage 5, the risk is even higher than that of those receiving dialysis. Further strategies of TB control need to consider this high-risk group.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization. Group at risk: WHO report on the tuberculosis epidemic. Geneva: World Health Organization; 1996. World Health Organization. Group at risk: WHO report on the tuberculosis epidemic. Geneva: World Health Organization; 1996.
2.
go back to reference World Health Organization. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018. World Health Organization. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018.
3.
go back to reference Organization WH: Global Tuberculosis Report. 2015. Organization WH: Global Tuberculosis Report. 2015.
4.
go back to reference Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, Greenaway C. Risk of active tuberculosis in patients with Cancer: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:635–44.CrossRef Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, Greenaway C. Risk of active tuberculosis in patients with Cancer: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:635–44.CrossRef
5.
go back to reference Wejse C. Tuberculosis elimination in the post millennium development goals era. Int J Infect Dis. 2015;32:152–5.CrossRef Wejse C. Tuberculosis elimination in the post millennium development goals era. Int J Infect Dis. 2015;32:152–5.CrossRef
6.
go back to reference Lonnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45:928–52.CrossRef Lonnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45:928–52.CrossRef
7.
go back to reference Rose DN. Benefits of screening for latent mycobacterium tuberculosis infection. Arch Intern Med. 2000;160:1513–21.CrossRef Rose DN. Benefits of screening for latent mycobacterium tuberculosis infection. Arch Intern Med. 2000;160:1513–21.CrossRef
8.
go back to reference Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, et al. Management of latent mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563–76.CrossRef Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, et al. Management of latent mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563–76.CrossRef
9.
go back to reference Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.CrossRef Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.CrossRef
10.
go back to reference Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease--what have we learned in 10 years? Semin Dial. 2010;23:498–509.CrossRef Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease--what have we learned in 10 years? Semin Dial. 2010;23:498–509.CrossRef
11.
go back to reference Maizel J, Deransy R, Dehedin B, Secq E, Zogheib E, Lewandowski E, Tribouilloy C, Massy ZA, Choukroun G, Slama M. Impact of non-dialysis chronic kidney disease on survival in patients with septic shock. BMC Nephrol. 2013;14:77.CrossRef Maizel J, Deransy R, Dehedin B, Secq E, Zogheib E, Lewandowski E, Tribouilloy C, Massy ZA, Choukroun G, Slama M. Impact of non-dialysis chronic kidney disease on survival in patients with septic shock. BMC Nephrol. 2013;14:77.CrossRef
12.
go back to reference Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, Stehman-Breen C, Gillen D, Bleyer AJ, Hirsch C, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005;16:3728–35.CrossRef Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, Stehman-Breen C, Gillen D, Bleyer AJ, Hirsch C, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005;16:3728–35.CrossRef
13.
go back to reference Romanowski K, Clark EG, Levin A, Cook VJ, Johnston JC. Tuberculosis and chronic kidney disease: an emerging global syndemic. Kidney Int. 2016;90:34–40.CrossRef Romanowski K, Clark EG, Levin A, Cook VJ, Johnston JC. Tuberculosis and chronic kidney disease: an emerging global syndemic. Kidney Int. 2016;90:34–40.CrossRef
14.
go back to reference Cheng KC, Liao KF, Lin CL, Liu CS, Lai SW. Chronic kidney disease correlates with increased risk of pulmonary tuberculosis before initiating renal replacement therapy: a cohort study in Taiwan. Medicine (Baltimore). 2018;97:e12550.CrossRef Cheng KC, Liao KF, Lin CL, Liu CS, Lai SW. Chronic kidney disease correlates with increased risk of pulmonary tuberculosis before initiating renal replacement therapy: a cohort study in Taiwan. Medicine (Baltimore). 2018;97:e12550.CrossRef
15.
go back to reference Centers of Disease Control DoH, R.O.C. (Taiwan). CDC annual report 2019. Taipei: Centers of Disease Control, Department of Health, R.O.C. (Taiwan); 2019. Centers of Disease Control DoH, R.O.C. (Taiwan). CDC annual report 2019. Taipei: Centers of Disease Control, Department of Health, R.O.C. (Taiwan); 2019.
16.
go back to reference Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–83.CrossRef Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–83.CrossRef
17.
go back to reference National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
18.
go back to reference Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney disease. Lancet. 2017;389:1238–52.CrossRef Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney disease. Lancet. 2017;389:1238–52.CrossRef
19.
go back to reference Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic Kidney disease and Dialysis patients. Nutrients. 2017;9:1.CrossRef Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic Kidney disease and Dialysis patients. Nutrients. 2017;9:1.CrossRef
20.
go back to reference Peraldi MN, Berrou J, Metivier F, Toubert A. Natural killer cell dysfunction in uremia: the role of oxidative stress and the effects of dialysis. Blood Purif. 2013;35(Suppl 2):14–9.CrossRef Peraldi MN, Berrou J, Metivier F, Toubert A. Natural killer cell dysfunction in uremia: the role of oxidative stress and the effects of dialysis. Blood Purif. 2013;35(Suppl 2):14–9.CrossRef
21.
go back to reference Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006;118:83–91.CrossRef Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006;118:83–91.CrossRef
22.
go back to reference Anding K, Gross P, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant. 2003;18:2067–73.CrossRef Anding K, Gross P, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant. 2003;18:2067–73.CrossRef
23.
go back to reference Shu CC, Hsu CL, Wei YF, Lee CY, Liou HH, Wu VC, Yang FJ, Lin HH, Wang JY, Chen JS, et al. Risk of tuberculosis among patients on Dialysis: the predictive value of serial interferon-gamma release assay. Medicine (Baltimore). 2016;95:e3813.CrossRef Shu CC, Hsu CL, Wei YF, Lee CY, Liou HH, Wu VC, Yang FJ, Lin HH, Wang JY, Chen JS, et al. Risk of tuberculosis among patients on Dialysis: the predictive value of serial interferon-gamma release assay. Medicine (Baltimore). 2016;95:e3813.CrossRef
24.
go back to reference Li SY, Chen TJ, Chung KW, Tsai LW, Yang WC, Chen JY, Chen TW. Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study. Clin Microbiol Infect. 2011;17:1646–52.CrossRef Li SY, Chen TJ, Chung KW, Tsai LW, Yang WC, Chen JY, Chen TW. Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study. Clin Microbiol Infect. 2011;17:1646–52.CrossRef
25.
go back to reference Cho PJ, Wu CY, Johnston J, Wu MY, Shu CC, Lin HH. Progression of chronic kidney disease and the risk of tuberculosis: an observational cohort study. Int J Tuberc Lung Dis. 2019;23:555–62.CrossRef Cho PJ, Wu CY, Johnston J, Wu MY, Shu CC, Lin HH. Progression of chronic kidney disease and the risk of tuberculosis: an observational cohort study. Int J Tuberc Lung Dis. 2019;23:555–62.CrossRef
26.
go back to reference Control TCoD: Taiwan tuberculosis control report 2017. 2017. Control TCoD: Taiwan tuberculosis control report 2017. 2017.
27.
go back to reference Hauser AB, Stinghen AE, Kato S, Bucharles S, Aita C, Yuzawa Y, Pecoits-Filho R. Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int. 2008;28(Suppl 3):S183–7.PubMed Hauser AB, Stinghen AE, Kato S, Bucharles S, Aita C, Yuzawa Y, Pecoits-Filho R. Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int. 2008;28(Suppl 3):S183–7.PubMed
28.
go back to reference Liu J, Yan J, Wan Q, Ye Q, Huang Y. The risk factors for tuberculosis in liver or kidney transplant recipients. BMC Infect Dis. 2014;14:387.CrossRef Liu J, Yan J, Wan Q, Ye Q, Huang Y. The risk factors for tuberculosis in liver or kidney transplant recipients. BMC Infect Dis. 2014;14:387.CrossRef
29.
go back to reference Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266–77.CrossRef Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266–77.CrossRef
30.
go back to reference Gao L, Li X, Liu J, Wang X, Lu W, Bai L, Xin H, Zhang H, Li H, Zhang Z, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017;17:1053–61.CrossRef Gao L, Li X, Liu J, Wang X, Lu W, Bai L, Xin H, Zhang H, Li H, Zhang Z, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017;17:1053–61.CrossRef
31.
go back to reference Shu CC, Wu HD, Yu MC, Wang JT, Lee CH, Wang HC, Wang JY, Lee LN, Yu CJ, Yang PC. Taiwan anti-mycobacteria investigation G: use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore). 2010;89:53–61.CrossRef Shu CC, Wu HD, Yu MC, Wang JT, Lee CH, Wang HC, Wang JY, Lee LN, Yu CJ, Yang PC. Taiwan anti-mycobacteria investigation G: use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore). 2010;89:53–61.CrossRef
32.
go back to reference Yang Y, Thumboo J, Tan BH, Tan TT, Fong CHJ, Ng HS, Fong KY. The risk of tuberculosis in SLE patients from an Asian tertiary hospital. Rheumatol Int. 2017;37:1027–33.CrossRef Yang Y, Thumboo J, Tan BH, Tan TT, Fong CHJ, Ng HS, Fong KY. The risk of tuberculosis in SLE patients from an Asian tertiary hospital. Rheumatol Int. 2017;37:1027–33.CrossRef
33.
go back to reference Handa R, Upadhyaya S, Kapoor S, Jois R, Pandey BD, Bhatnagar AK, Khanna A, Goyal V, Kumar K. Tuberculosis and biologics in rheumatology: a special situation. Int J Rheum Dis. 2017;20:1313–25.CrossRef Handa R, Upadhyaya S, Kapoor S, Jois R, Pandey BD, Bhatnagar AK, Khanna A, Goyal V, Kumar K. Tuberculosis and biologics in rheumatology: a special situation. Int J Rheum Dis. 2017;20:1313–25.CrossRef
Metadata
Title
The impact on incident tuberculosis by kidney function impairment status: analysis of severity relationship
Authors
Chin-Chung Shu
Yu-Feng Wei
Yi-Chun Yeh
Hsien-Ho Lin
Chung-Yu Chen
Ping-Huai Wang
Shih-Lung Cheng
Jann-Yuan Wang
Chong-Jen Yu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-1294-5

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.